A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors
about
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapyEnhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancersDrug therapy for hereditary cancersNanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity.Preoperative Systemic Treatment in BRCA-Positive Breast Cancer Patients: Case Report and Review of the Literature.Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds.Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis.Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined "Complementary Lethality".Systemic treatment for hereditary cancers: a 2012 update.Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK.Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer.The clinical development of inhibitors of poly(ADP-ribose) polymerase.Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.Systemic therapy options in BRCA mutation-associated breast cancer.DNA interstrand cross-link repair: understanding role of Fanconi anemia pathway and therapeutic implications.Opportunities and hurdles in the treatment of BRCA1-related breast cancer.Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer.Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor.Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping.BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i.ID1 affects the efficacy of radiotherapy in glioblastoma through inhibition of DNA repair pathways.Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer.Complete response to orally administered melphalan in malignant pleural effusion from an occult female genital organ primary neoplasm with BRCA1/2 mutations: a case report.
P2860
Q33827045-16091056-C644-4C28-8C5C-82F6A67ABDC1Q33965570-84A49836-63C9-4D89-8D89-CB6534EEB36CQ34305493-D365C797-88E0-4EC4-8E13-1BEDA6D14AF0Q34663583-221B9893-93D6-4E1B-B200-1C4FD528EBF6Q35014762-5FD90613-D177-4FFE-8B0E-B99FF877C88FQ35208929-CE40D9DD-CD2D-46A5-99EF-32C28E0E5E47Q35534276-727300EB-3C7D-4474-B367-13AC86B27386Q35976084-3525E064-326D-441F-9ACA-896B441BF553Q36563979-C6479E9D-AB19-4E65-946A-641184BC8AC0Q36729649-4D663AB9-B332-49FF-A11F-A45AE446A767Q36738376-5218E39C-9490-427A-907F-7D315703D045Q36755366-A2BF8F59-C806-4416-B088-782EB683A908Q37342850-7DEA5053-6E20-4D46-A150-6F365F60B2E4Q37775105-F99026BE-96B6-48BD-9D47-3F19F32BB67BQ37834139-57E69AF5-E9CE-4F01-AD5B-9D5E493AB064Q37933098-24DAA4AC-1F75-42E2-BB63-AEEC5B91C47EQ38025991-FF48E41E-881B-4CE2-8D26-A6D800CA9360Q38121955-B5A62DD1-80F1-42A2-8770-047D75275C66Q38129725-2E5546D5-6395-4672-A1F1-E0C27D3AA81EQ38798405-115BB02F-2F33-450E-A018-A0EAA586A8FAQ39598910-B0F9E26A-3895-4DB5-97DD-9B19BE6DD275Q41077638-320D9781-210C-4FEF-B433-F7CBC7ED6126Q42199595-9F977BBD-CB54-451A-BA18-C201C9C354BEQ42280757-4B6D41D1-A65D-4DDA-943D-167AD3F81C19Q48104565-9A34B09A-67A8-4529-B38C-13AF13AC83CAQ48178463-21EAD967-DC72-4A89-BCA2-36F0EE67C9D1Q51272824-EC91BCE1-B56B-478C-85D8-2179EDA82DBCQ55021702-84622970-D05A-49E7-8AAA-C62AA56CF407Q55316688-60BA857C-8C3A-46CE-821C-BEC612038092
P2860
A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A high-throughput pharmaceutic ...... against BRCA2-deficient tumors
@ast
A high-throughput pharmaceutic ...... against BRCA2-deficient tumors
@en
A high-throughput pharmaceutic ...... gainst BRCA2-deficient tumors.
@nl
type
label
A high-throughput pharmaceutic ...... against BRCA2-deficient tumors
@ast
A high-throughput pharmaceutic ...... against BRCA2-deficient tumors
@en
A high-throughput pharmaceutic ...... gainst BRCA2-deficient tumors.
@nl
prefLabel
A high-throughput pharmaceutic ...... against BRCA2-deficient tumors
@ast
A high-throughput pharmaceutic ...... against BRCA2-deficient tumors
@en
A high-throughput pharmaceutic ...... gainst BRCA2-deficient tumors.
@nl
P2093
P2860
P1476
A high-throughput pharmaceutic ...... against BRCA2-deficient tumors
@en
P2093
Bastiaan Evers
David A Egan
David J Adams
Eline van der Burg
Jos Jonkers
Pauline Edser
Peter Bouwman
Tanya M Braumuller
P2860
P304
P356
10.1158/1078-0432.CCR-09-2434
P407
P577
2009-12-15T00:00:00Z